

REMARKS

Claim1 has been amended to improve its language without change of substance.

The examiner rejects the claims under 35 USC 102(b) over Coe et al This, however is improper. The present application claims priority from Serial No 60/358917 filed on February 22, 2002. This is less than one year after the publication of Coe on November 1, 2001.

Even if Coe had been a valid reference, however, it would not anticipate the present claims.

As noted in MPEP 2131, quoting *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987),

"A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference."


Essential steps in the present claims are determining the LDL-cholesterol value for patients and administering the specified compounds to patients whose LDL was determined to be below 109 mg/dl. Coe does not contain the slightest hint of such steps.

Coe's invention is to combine a cholinesterase inhibitor (a class which includes galanthamine) with an NRPA to treat cognitive dysfunction in wide classes of patients. There is no suggestion to use galanthamine or any of the other compounds specified in the present application as the only active in treating the particular class of patients specified in the present claims,

It is therefore submitted that the present invention meets the requirements of 35 USC 102.

In view of the foregoing, it is submitted that this application is in order for allowance and an early action to this end is respectfully solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'John Richards', is positioned above a horizontal dotted line.

JOHN RICHARDS

C/O LADAS & PARRY LLP

1040 AVENUE OF THE AMERICAS

NEW YORK, NEW YORK 10018

REG. NO. 31,053

TEL. NO. (212) 708-1915